Diagnosis and classification of myelodysplastic syndromes.
Hasserjian RP, Germing U, Malcovati L.
Blood. 2023 Dec 28;142(26):2247-2257. doi: 10.1182/blood.2023020078.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M.
Blood. 2020 Jul 9;136(2):157-170. doi: 10.1182/blood.2020004850.
Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment.
Acha P, Mallo M, Solé F.
Cancers (Basel). 2022 Nov 10;14(22):5531. doi: 10.3390/cancers14225531.
Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
Jädersten M, Karsan A.
Haematologica. 2011 Feb;96(2):177-80. doi: 10.3324/haematol.2010.038281.
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion.
Montoro MJ, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, Kubota Y, Schulz FI, Meggendorfer M, Briski R, Al Ali N, Xicoy B, López-Cadenas F, Bosch F, González T, Eder LN, Jerez A, Wang YH, Campagna A, Santini V, Bernal Del Castillo T, Such E, Tien HF, Diaz Varela N, Platzbecker U, Haase D, Díez-Campelo M, Della Porta M, Garcia-Manero G, Wiseman DH, Germing U, Maciejewski JP, Komrokji RS, Sole F, Haferlach T, Valcárcel D.
Blood. 2024 Oct 17;144(16):1722-1731. doi: 10.1182/blood.2024023840.
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG; International Consortium on Myelodysplastic Syndromes.
Lancet Haematol. 2024 Nov;11(11):e862-e872. doi: 10.1016/S2352-3026(24)00251-5. Epub 2024 Oct 9.
Images from the Haematologica Atlas of Hematologic Cytology: myelodysplastic syndrome with isolated del(5q).
Invernizzi R.
Haematologica. 2022 Oct 1;107(10):2285. doi: 10.3324/haematol.2022.281643.
[Myelodysplastic syndrome classification].
Ghariani I, Braham N, Hassine M, Kortas M.
Ann Biol Clin (Paris). 2013 Mar-Apr;71(2):139-44. doi: 10.1684/abc.2013.0804.
Age, Blasts, Performance Status and Lenalidomide Therapy Influence the Outcome of Myelodysplastic Syndrome With Isolated Del(5q): A Study of 58 South American Patients.
Azevedo RS, Belli C, Bassolli L, Ferri L, Perusini MA, Enrico A, Pereira T, Junior W, Buccheri V, Pinheiro RF, Magalhaes SM, Schuster S, Castelli JB, Traina F, Rocha V, Velloso E.
Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):e1-e6. doi: 10.1016/j.clml.2021.07.026. Epub 2021 Jul 25.
Gaucher disease and myelodysplastic syndrome with isolated del(5q).
Villarrubia J, Rodríguez-Gambarte JD, Abalo L, Vallés A, Alonso-Domínguez JM, Velasco-Rodríguez D.
Br J Haematol. 2014 Apr;165(2):164. doi: 10.1111/bjh.12798. Epub 2014 Feb 24.
